Recent insights into eukaryotic translation initiation factors 5A1 and 5A2 and their roles in human health and disease

Cancer Cell Int. 2020 Apr 29:20:142. doi: 10.1186/s12935-020-01226-7. eCollection 2020.

Abstract

The eukaryotic translation initiation factor 5A1 (eIF5A1) and its homolog eIF5A2 are the only two human proteins containing the unique post-translational modification-hypusination, which is essential for the function of these two proteins. eIF5A1 was initially identified as a translation initiation factor by promoting the first peptide bond formation of protein during translation; however, recent results suggest that eIF5A1 also functions as a translation elongation factor. It has been shown that eIF5A1 is implicated in certain human diseases, including diabetes, several human cancer types, viral infections and diseases of neural system. Meanwhile, eIF5A2 is overexpressed in many cancers, and plays an important role in the development and progression of cancers. As multiple roles of these two factors were observed among these studies, therefore, it remains unclear whether they act as oncogene or tumor suppressor. In this review, the recent literature of eIF5As and their roles in human diseases, especially in human cancers, will be discussed.

Keywords: Biomarkers; Eukaryotic translation initiation factor; Human cancers; Hypusination; Post-translational modifications; eIF5A1; eIF5A2.

Publication types

  • Review